These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 17073516)

  • 21. The role of glimepiride in the effective management of Type 2 diabetes.
    Davis SN
    J Diabetes Complications; 2004; 18(6):367-76. PubMed ID: 15531188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gliquidone versus metformin: differential effects on aorta in streptozotocin induced diabetic rats.
    Tan Z; Xu Z; Gui Q; Wu W; Yang Y
    Chin Med J (Engl); 2014; 127(7):1298-303. PubMed ID: 24709184
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mechanism of action of gliquidone (author's transl)].
    Zilker T; Ermler R; Henderkott U; Bottermann P
    Dtsch Med Wochenschr; 1975 Aug; 100(35):1733-4, 1739-41. PubMed ID: 808405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic optimisation of oral hypoglycaemic therapy.
    Marchetti P; Giannarelli R; di Carlo A; Navalesi R
    Clin Pharmacokinet; 1991 Oct; 21(4):308-17. PubMed ID: 1760902
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma.
    Sener A; Akkan AG; Malaisse WJ
    Acta Diabetol; 1995 Mar; 32(1):64-8. PubMed ID: 7612921
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Effect of short term hypoglycemic treatment with gliclazide and gliquidone on platelet function in patients with diabetes mellitus type II].
    Grzeszczak W; Strojek K
    Pol Tyg Lek; 1993 Apr; 48 Suppl 1():38-9. PubMed ID: 8516206
    [No Abstract]   [Full Text] [Related]  

  • 27. [Pharmacodynamics of second-generation sulfonylureas: dose-effect curve of gliquidone in type II diabetics].
    Procacci V; Giovine A; Roberto MG; Ronchi AM; Lasorsa G; Vendemiale G; Stufano N; Altomare E
    Boll Soc Ital Biol Sper; 1988 Aug; 64(8):731-8. PubMed ID: 3214573
    [No Abstract]   [Full Text] [Related]  

  • 28. Management of sulfonylurea-treated monogenic diabetes in pregnancy: implications of placental glibenclamide transfer.
    Shepherd M; Brook AJ; Chakera AJ; Hattersley AT
    Diabet Med; 2017 Oct; 34(10):1332-1339. PubMed ID: 28556992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide.
    Massi-Benedetti M; Herz M; Pfeiffer C
    Horm Metab Res; 1996 Sep; 28(9):451-5. PubMed ID: 8911982
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Kinetics-effect relations of insulin-releasing drugs in patients with type 2 diabetes: brief overview.
    Melander A
    Diabetes; 2004 Dec; 53 Suppl 3():S151-5. PubMed ID: 15561903
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of gliquidone, glibenclamide, gliclazide and glipizide in middle-aged and aged subjects.
    Courtois P; Sener A; Herbaut C; Turc A; Malaisse WJ
    Res Commun Mol Pathol Pharmacol; 1999 Feb; 103(2):211-22. PubMed ID: 10461687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of pH and complexation on transdermal permeation of gliquidone.
    Sridevi S; Diwan PV
    Pharmazie; 2002 Sep; 57(9):632-4. PubMed ID: 12369452
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The use of sulphonylureas in the elderly.
    Graal MB; Wolffenbuttel BH
    Drugs Aging; 1999 Dec; 15(6):471-81. PubMed ID: 10641958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Sulfonylureas and daily blood glucose profiles in elderly diabetics].
    Oba K; Koibuchi H; Okazaki K; Igari Y; Inuzuka Y; Yano M; Yamaguchi Y; Ajiro Y; Satoh S; Nagai S; Suzuki T; Nakano H; Metori S
    Nihon Ronen Igakkai Zasshi; 1999 Oct; 36(10):715-20. PubMed ID: 10614126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus.
    Campbell RK
    Ann Pharmacother; 1998 Oct; 32(10):1044-52. PubMed ID: 9793597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Effect of gliquidone and glibenclamide following oral administration].
    Ziler T; Waldthaler A; Ermler R; Bottermann P
    MMW Munch Med Wochenschr; 1975 Sep; 117(36):1423-4. PubMed ID: 809687
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic-pharmacodynamic relationships of oral hypoglycaemic agents. An update.
    Marchetti P; Navalesi R
    Clin Pharmacokinet; 1989 Feb; 16(2):100-28. PubMed ID: 2656043
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evidence for more than one binding site for sulfonylureas in insulin-secreting cells.
    Verspohl EJ; Ammon HP; Mark M
    J Pharm Pharmacol; 1990 Apr; 42(4):230-5. PubMed ID: 1974288
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The use of the hypoglycemic preparation gliquidone in patients with digestive organ diseases combined with diabetes mellitus].
    Degtiareva II; Lodianaia EV; Opanasiuk ND; Palladina OL
    Lik Sprava; 1995; (7-8):84-7. PubMed ID: 8846383
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.